NPM1 and acute myeloid leukemia: When focusing on individual gene mutations, data from the literature indicate that NPM1-mut (25–35% of AML patients in general and 45–60% of cytogenetically normal AML) or FLT3-ITD patients (~20% of cases) had a higher CD33 expression compared to wildtype (wt) cases [80,105,106] and may benefit from GO treatment.